The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …

Chimeric antigen receptor (CAR) T cell-based immunotherapy, approved by the US Food
and Drug Administration, has shown curative potential in patients with haematological …

Traceless physical cues are desirable for remote control of the in situ production and real-
time dosing of biopharmaceuticals in cell-based therapies. However, current optogenetic …

Chimeric antigen receptor (CAR)-T cell therapy has become one of the hot topics in tumor
immunity research in recent years. Although CAR-T cell therapy is highly effective in treating …

Background Opsin‐based optogenetics has emerged as a powerful biomedical tool using
light to control protein conformation. Such capacity has been initially demonstrated to control …

Optogenetics enables genome manipulations with high spatiotemporal resolution, opening
exciting possibilities for fundamental and applied biological research. Here, we report the …

Engineered cell-based therapies have emerged as a new paradigm in modern medicine,
with several engineered T cell therapies currently approved to treat blood cancers and many …

Escherichia coli biofilm may form naturally on biotic and abiotic surfaces; this represents a
promising approach for efficient biochemical production in industrial fermentation. Recently …

Among the many oncology therapies, few have generated as much excitement as CAR-T.
The success of CAR therapy would not have been possible without the many discoveries …